Exome Sequencing Catches 90% of Familial Hypercholesterolemia Cases Missed by Standard Criteria
A Mayo Clinic study of 84,000+ participants shows genetic sequencing identifies FH far more accurately than clinical scores alone.
Summary
Familial hypercholesterolemia (FH) is a common inherited condition that dramatically raises heart attack risk, yet most people who carry the genetic mutations never get diagnosed. A large Mayo Clinic study enrolled over 84,000 participants across three US cities and used Exome+ sequencing to screen for FH-causing variants in three key genes. Nearly 0.5% of participants carried a likely pathogenic or pathogenic variant — and a striking 90% of those were newly diagnosed. Most alarming: standard clinical diagnostic criteria (the Dutch Lipid Clinic Network score) would have missed nearly 70% of confirmed genetic carriers. Only 10% of carriers had their LDL cholesterol under control, and over 22% already had a history of coronary artery disease. This study makes a compelling case that genetic sequencing should become a routine screening tool for FH.
Detailed Summary
Familial hypercholesterolemia (FH) is one of the most common inherited disorders in medicine, affecting roughly 1 in 200 to 1 in 300 people worldwide. It causes lifelong elevation of LDL cholesterol and sharply increases the risk of premature heart attack and coronary artery disease. Despite this, most FH carriers remain undiagnosed throughout their lives — a dangerous gap that this study set out to address.
Researchers at Mayo Clinic enrolled 84,413 participants across three geographically and racially diverse sites in Rochester (MN), Phoenix (AZ), and Jacksonville (FL) as part of the Tapestry study. All participants underwent Exome+ sequencing, with results returned for pathogenic or likely pathogenic variants in three FH-associated genes: APOB, LDLR, and PCSK9. Clinical records were reviewed for cardiovascular history, lipid levels, medications, and demographics.
The sequencing identified 419 participants with likely pathogenic or pathogenic FH variants — a prevalence of 0.50%. The breakdown was 298 LDLR variants, 116 APOB variants, and 5 PCSK9 variants. Critically, nearly 90% of these carriers were newly diagnosed at the time of the study, underscoring how profoundly underdetected FH remains in routine clinical care. Even more striking, only 30.8% of genetically confirmed FH carriers would have met diagnostic criteria under the widely used Dutch Lipid Clinic Network (DLCN) scoring system, revealing a massive false-negative rate for this clinical tool.
Clinical outcomes among carriers were concerning. Only 10% had LDL cholesterol at goal levels, 27.5% were not on any cholesterol-lowering medication, and 22.4% had already experienced coronary artery disease. These findings highlight the real cardiovascular consequences of missed diagnoses.
The study strongly supports integrating germline genetic sequencing into routine health screening programs to identify FH carriers before cardiovascular events occur. Limitations include that the summary is based on the abstract only, and the predominantly health-system-engaged population may not reflect the general public.
Key Findings
- 0.5% of 84,000+ participants carried pathogenic FH variants — nearly 90% were newly diagnosed.
- Standard Dutch Lipid Clinic Network criteria missed nearly 70% of genetically confirmed FH cases.
- Only 10% of confirmed FH carriers had LDL cholesterol at goal levels.
- 22.4% of FH carriers already had a history of coronary artery disease at time of identification.
- LDLR variants were most common (298), followed by APOB (116) and PCSK9 (5).
Methodology
The Tapestry study enrolled 84,413 participants across three US sites and performed Exome+ sequencing (Helix Inc.) with return of results for APOB, LDLR, and PCSK9 variants. Chart review collected demographics, cardiovascular history, lipid levels, and medication use. The study was registered as a clinical trial (NCT05212428).
Study Limitations
This summary is based on the abstract only, as the full paper was not available. The study population was recruited through a healthcare system, which may introduce selection bias toward more health-engaged individuals. Two co-authors are employees of Helix Inc., the sequencing company used in the study, which represents a potential conflict of interest.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: